Company Overview of NanoBio Corporation
NanoBio Corporation, a biopharmaceutical company, focused on developing and commercializing intranasal and intramuscular vaccines. The company offers vaccines targeting respiratory, sexually transmitted, and other diseases. It offers NanoStat Platform that utilizes a novel oil-in-water emulsion adjuvant to enable vaccines that elicit broad protection against disease. The company’s lead product candidates include vaccines for RSV, herpes simplex virus-2, H5 influenza, human immunodeficiency virus, seasonal and pandemic influenza, pertussis, and anthrax. It has a strategic alliance with Merck & Co., Inc. NanoBio Corporation was founded in 1999 and is based in Ann Arbor, Michigan.
2311 Green Road
Ann Arbor, MI 48105
Founded in 1999
Key Executives for NanoBio Corporation
Chief Executive Officer and Director
Senior Vice President of Vaccine Research and Development
Member of Scientific Team
Compensation as of Fiscal Year 2014.
NanoBio Corporation Key Developments
NanoBio Corporation Announces Licensing Agreement with a Subsidiary of Merck & Co., Inc
Mar 26 14
NanoBio Corporation announced a licensing agreement with a subsidiary of Merck & Co. Inc., known as MSD outside the United States and Canada, for the use of its nanoemulsion (NE) adjuvant technology. Under the agreement, Merck receives exclusive rights to NanoBio's NE adjuvant for use in an intranasal respiratory syncytial virus (RSV) vaccine and non-exclusive rights for use in an intranasal seasonal influenza and/or universal seasonal influenza ("Flu") vaccine. NanoBio receives an upfront payment and is eligible to receive milestone payments based on Merck RSV and Flu vaccine candidates' development and regulatory approvals, as well as royalties on sales of any Merck RSV or Flu vaccines that ultimately use the NanoBio NE adjuvant technology. NanoBio's NanoStat(R) technology platform employs a novel oil-in-water nanoemulsion that can incorporate, deliver and adjuvant multiple antigen types. The NE adjuvant is effective when administered via intranasal, intramuscular or subcutaneous vaccination. In recent studies, NanoBio has demonstrated that intranasal vaccination elicits robust systemic and mucosal immunity, thereby offering enhanced protection against respiratory infections and sexually transmitted diseases compared to intramuscular vaccination.
NanoBio Corporation Receives Contract from National Institute of Allergy and Infectious Diseases
Oct 31 13
NanoBio Corporation announced that it has received a contract from the National Institute of Allergy and Infectious Diseases. The USD 5.5 million contract is for developing a nanoemulsion adjuvant for use with a pandemic influenza vaccine. The funds will be utilised to support the research and development of NanoVax-Panflu, which combines NanoBio's proprietary NE adjuvant with a plant-based recombinant H5 pandemic influenza antigen.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries